Clinical trials
Completed Observational trials in Mexico
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
374 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 11 |
| 2007 | 10 |
| 2008 | 9 |
| 2009 | 13 |
| 2010 | 15 |
| 2011 | 14 |
| 2012 | 15 |
| 2013 | 13 |
| 2014 | 17 |
| 2015 | 17 |
| 2016 | 19 |
| 2017 | 23 |
| 2018 | 23 |
| 2019 | 29 |
| 2020 | 44 |
| 2021 | 34 |
| 2022 | 12 |
| 2023 | 12 |
| 2024 | 20 |
| 2025 | 5 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 374 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Instituto Mexicano del Seguro Social | 26 |
| Bayer | 21 |
| AstraZeneca | 19 |
| Hospital Universitario Dr. Jose E. Gonzalez | 13 |
| Novo Nordisk A/S | 13 |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 11 |
| Hoffmann-La Roche | 7 |
| Universidad Autonoma de San Luis Potosí | 7 |
| AbbVie | 6 |
| Bristol-Myers Squibb | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 30 |
| Diabetes Mellitus, Type 2 | 13 |
| Obesity | 13 |
| Neoplasms | 11 |
| Diabetes Mellitus | 10 |
| Breast Neoplasms | 9 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Anxiety Disorders | 7 |
| Arthritis, Rheumatoid | 7 |
| Hypertension | 6 |
Trials
Showing 1 to 25 of 374. Each trial links to its page on Pharma Observatory.
274 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.